Xencor plans pivotal study of XmAb819 in advanced kidney cancer in 2027

XNCR•2026-10-19

Xencor plans a registration-enabling monotherapy study of XmAb819 in advanced clear cell renal cell carcinoma in 2027. The company will present Phase 1 results at ESMO on October 25, 2026.

1. Study plans and results

Xencor plans a registration-enabling monotherapy study of XmAb819 in advanced clear cell renal cell carcinoma in 2027. Intravenous expansion cohorts are evaluating doses to support selection for the planned Phase 3 pivotal trial; Phase 1 results are scheduled for presentation at ESMO on October 25, 2026.

Xencor plans pivotal study of XmAb819 in advanced kidney cancer in 2027

1. Study plans and results

Related News

KKR to sell Infinity Transportation to Ares for $2.9 billion

KKR to sell railcar-leasing company Infinity to Ares for $2.9 billion

Axcelis Technologies target price cut to $165 from $198

Talen Energy Corporation: Raymond James cuts target price to $442 from $449

Indian bonds give up day's gains as oil price spike adds to rate hike fears